Breaking News

SAP Agrees to Buy Concur Technologies for Enterprise Value of $8.3 Billion
Tweet TWEET

BioClinica and CoreLab Partners Are One

  BioClinica and CoreLab Partners Are One

     Combined Company Creates Clear Leader for Imaging Core Lab Services

Business Wire

NEWTOWN, Pa. -- March 14, 2013

BioClinica^®, Inc., (NASDAQ: BIOC), a global provider of clinical trial
management services, announced today that JLL Partners and Ampersand Capital
Partners, two leading middle market private equity firms, have completed their
acquisition of BioClinica and CoreLab Partners and have combined the two
companies under the name BioClinica.

This merger brings together two of the most experienced and trusted
authorities in medical imaging management for clinical trials and creates a
new standard in imaging core lab services, cardiovascular safety monitoring,
and eClinical trial management solutions.

“The unification of BioClinica and CoreLab Partners will enhance the existing
service quality and technological innovation supported by scientific and
medical expertise that have long been hallmarks of these two companies,” said
Mark Weinstein, who will lead the newly combined company as President and CEO.
“This merger produces a stronger BioClinica that is better able to support
pharmaceutical, biotechnology, and medical device development.”

Dan Agroskin, Managing Director of JLL Partners said, “JLL has spent a
significant amount of time gaining an understanding of the pharmaceutical
outsourcing sector and, as a result, we are pleased to have made these two
acquisitions. This combination brings together two industry leading companies
that we are confident will continue to deliver a strong service offering to
their customers. We are excited by the growth potential of this newly formed
platform, and we look forward to working with the talented management of
BioClinica and CoreLab Partners as they continue to enhance their
best-in-class capabilities.”

The combination of BioClinica and CoreLab Partners establishes a clear
industry leader for imaging core lab services and further complements
BioClinica’s other service offerings. BioClinica is better positioned to offer
customers comprehensive support for clinical trials with extensive
capabilities, including:

Scientific and Medical Expertise

  *Unmatched scientific and medical expertise in therapeutic areas where
    imaging is critical such as oncology, neurology, musculoskeletal, and
    cardiology
  *A comprehensive suite of cardiovascular safety monitoring services with
    unrivaled scientific and technical leadership

Industry-Leading Technologies

  *Longstanding experience working across all imaging modalities
  *Combined strength in image acquisition protocols, electronic transfer,
    management, and central review of medical images
  *Leading eClinical solutions for clinical trial management, electronic data
    capture, randomization, and supply chain forecasting and optimization

Recognized Clinical Trial Experience

  *A combined total of 50 FDA approved drugs, including 33 in oncology
  *Demonstrated flexibility to engage in multiple partnership models and the
    independence to collaborate with a sponsor’s choice of full-service
    Contract Research Organizations (CROs)
  *Global operational support in North America, China, Japan, Germany, The
    Netherlands, and France

Follow BioClinica on the Trial Blazers blog at http://www.bioclinica.com/blog,
and on twitter at http://twitter.com/bioclinica.

About the BioClinica, Inc. Merger Transaction

On March 13, 2013, JLL Partners completed its acquisition of BioClinica
through the short-form merger of an entity affiliated with JLLPartners and
BioClinica. BioClinica is the surviving entity in the merger and is now
wholly-owned by affiliates of JLL Partners, Ampersand and certain other
investors. As of the close of business on March 13, 2013, BioClinica will no
longer trade on the Nasdaq Global Market.

In connection with the transaction, KeyBank National Association, CIT Finance
LLC and U.S. Bank National Association acted as the lead arrangers and joint
bookrunners for the financing, which consisted of $100 million of senior
secured facilities, including a $75 million term loan facility and $25 million
revolving facility, undrawn at close.

Excel Partners acted as financial advisor to BioClinica, and Morgan, Lewis &
Bockius LLP acted as legal counsel to BioClinica. Robert W. Baird acted as
financial advisor to CoreLab Partners and Edwards, Wildman Palmer LLP acted as
legal counsel to CoreLab Partners and Ampersand Capital Partners. Skadden,
Arps, Slate, Meagher & Flom LLP and Simpson Thacher Bartlett LLP acted as
legal counsel to JLL Partners.

About BioClinica

BioClinica is a leading global provider of integrated, technology-enhanced
clinical trial management services. A 2013 merger with CoreLab Partners
created a new standard for imaging core lab services including electronic
transfer, management, and independent review; cardiovascular safety monitoring
including automated ECG, Thorough QT studies, Holter monitoring, ambulatory
blood pressure monitoring and pulse wave analysis; and eClinical solutions for
electronic data capture, randomization, clinical trial management, and
clinical supply chain forecasting and optimization. BioClinica offers
unmatched scientific expertise with a team of respected medical researchers
and board certified, sub-specialty trained radiologists, cardiologists,
nuclear medicine physicians and oncologists. With more than 28 years of
experience and over 3,300 successful trials to date, BioClinica has supported
the development of many new medicines through all phases of the clinical trial
process. BioClinica operates state-of-the-art, regulatory-body-compliant
imaging core labs on two continents, and supports worldwide comprehensive
cardiovascular safety, and eClinical and data management services from offices
in the United States, Europe and Asia. For more information, please visit
www.bioclinica.com.

About JLL Partners

JLL Partners is a leading New York-based private equity investment firm with
approximately $4 billion of capital under management. JLL Partners’ investment
philosophy is to partner with outstanding management teams and invest in
companies that they can continue to grow into market leaders. JLL Partners has
invested in a variety of industries, with special focus on the healthcare and
pharmaceutical services industries. For more information, please visit
www.jllpartners.com.

About Ampersand

Ampersand Capital Partners, based in Boston, is a leading private equity firm
that focuses on middle market growth equity investments in the Healthcare
sector. Ampersand Capital Partners leverages its unique blend of private
equity and operating experience to build value and drive long-term performance
alongside its portfolio company management teams. For more information, please
visit www.ampersandcapital.com.

Certain matters discussed in this press release are “forward-looking
statements” intended to qualify for the safe harbors from liability
established by the Private Securities Litigation Reform Act of 1995. In
particular, the Company’s statements regarding trends in the marketplace and
potential future results are examples of such forward-looking statements. The
forward-looking statements include risks and uncertainties, including, but not
limited to, the consummation and the successful integration of current and
proposed acquisitions, the timing of projects due to the variability in size,
scope and duration of projects, estimates and guidance made by management with
respect to the Company’s financial results, backlog, critical accounting
policies, regulatory delays, clinical study results which lead to reductions
or cancellations of projects, and other factors, including general economic
conditions and regulatory developments, not within the Company’s control. The
factors discussed herein and expressed from time to time in the Company’s
filings with the Securities and Exchange Commission could cause actual results
and developments to be materially different from those expressed in or implied
by such statements. The forward-looking statements are made only as of the
date of this press release and the Company undertakes no obligation to
publicly update such forward-looking statements to reflect subsequent events
or circumstance. You should review the Company’s filings, especially risk
factors contained in the Form 10-K and the recent Form 10-Q.

Contact:

BioClinica, Inc.
Jim Dorsey, 267-757-3040
or
Trade Media
Diccicco Battista Communications
Morgan Dub Karpo, 484-342-3600
or
Investors
Porter, LeVay & Rose, Inc.
Michael Porter, 212-564-4700
 
Press spacebar to pause and continue. Press esc to stop.